Exhibit 99.1




First self-administered antibody therapy for HIV in late-stage clinical trials

Investor Presentation

March 2017

(OTCQB: CYDY) 1 www.cytodyn.com







Forward-Looking Statements


This presentation includes forward-looking statements and forward-looking information within the meaning of United States securities laws. These statements and information represent CytoDyn’s intentions, plans, expectations and beliefs, and are subject to numerous risks, uncertainties and other factors, of which many are beyond CytoDyn’s control. These factors could cause actual results to differ materially from such forward-looking statements or information. The words “believe,” “estimate,” “expect,” “intend,” “attempt,” “anticipate,” “foresee,” “plan,” and similar expressions and variations thereof, identify certain of such forward-looking statements or forward-looking information, which speak only as of the date on which they are made.

CytoDyn disclaims any intention or obligation to publicly update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements or forward-looking information. While it is impossible to identify or predict all such matters, these differences may result from, among other things, the inherent uncertainty of the timing and success of and expense associated with research, development, regulatory approval, and commercialization of CytoDyn’s products and product candidates, including the risks that clinical trials will not commence or proceed as planned; products appearing promising in early trials will not demonstrate efficacy or safety in larger-scale trials; future clinical trial data on CytoDyn’s products and product candidates will be unfavorable; funding for additional clinical trials may not be available; CytoDyn’s products may not receive marketing approval from regulators or, if approved, may fail to gain sufficient market acceptance to justify development and commercialization costs; competing products currently on the market or in development may reduce the commercial potential of CytoDyn’s products; CytoDyn, its collaborators or others may identify side effects after the product is on the market; or efficacy or safety concerns regarding marketed products, whether or not scientifically justified, may lead to product recalls, withdrawals of marketing approval, reformulation of the product, additional pre-clinical testing or clinical trials, changes in labeling of the product, the need for additional marketing applications, or other adverse events.

CytoDyn is also subject to additional risks and uncertainties, including risks associated with the actions of its corporate, academic, and other collaborators and government regulatory agencies; risks from market forces and trends; potential product liability; intellectual property litigation; environmental and other risks; and risks that current and pending patent protection for its products may be invalid, unenforceable, or challenged or fail to provide adequate market exclusivity. There are also substantial risks arising out of CytoDyn’s need to raise additional capital to develop its products and satisfy its financial obligations; the highly regulated nature of its business, including government cost- containment initiatives and restrictions on third-party payments for its products; the highly competitive nature of its industry; and other factors set forth in CytoDyn’s Annual Report on Form 10-K and other reports filed with the U.S. Securities and Exchange Commission.







CytoDyn and the HIV Landscape

Late-stage development of antibody for HIV therapies (two Phase 3 trials underway)

Large market of approximately $20 billion(1)

Big players with significant market share (2015)(2)

Gilead 56%

GSK 16%

BMS 12%

JNJ 9%

Merck 8%

CytoDyn’s PRO 140 offers strong and compelling differentiators for the market and its

1.3 million (3) patients (US only)



Minimal toxicity

Minimal side effects

Ease of compliance

Source: (1) http://www.transparencymarketresearch.com/hiv-market.html



Compilation from MedAdNews, Aug. 2016 from 2015 annual reports



GlobalDataEpiCastSeptember 2015







HIV is a virus called Human Immunodeficiency Virus

Once HIV is transmitted, it can only survive by entering T-cells

HIV half life = 24 hours

Viral Load (VL) is number of virus (HIV) particles per mL of blood

IfVL<40 copies/mL then the Transmission Rate ~ Zero (1)

High viral load is a major risk factor for transmission of HIV

Effective antiretroviral therapy can reduce transmission of HIV by more than 96% (1)

Treatment options (HAART –Current standard of care)

HIV replication process is called HIV life cycle and has 7 stages

Different classes of antiviral drugs are designed to stop HIV at different stages of HIV life cycle

HAART is comprised of 3 drugs from 2 classes –Today’s HIV drugs are oral pills

Problems with HAART


Side Effects


Source: (1) https://www.hivlawandpolicy.org/sites/www.hivlawandpolicy.org/files/Undetectable%20Blood%20Viral%20Load%20and%20HIV%20Transmission%20Risk%20-%20Results%20of%20a%20Systematic%20Review%20(CATIE).pdf






PRO 140 Advantages vs. Currently Approved Therapies

* The prevalence of antiretroviral drug resistance in the United States. http://www.ncbi.nlm.nih.gov/pubmed/15199315

PRO 140

HAART No drug resistancein patients on monotherapy for ~24 months 76% of patients have resistanceto 1 or more drugs*

Once-a-week, simple, painless, sub-cutaneous injections Lifelong adherence with only 30% of patients achieving suppressed viral load

No negative impact on immune function

No serious adverseevents (SAEs) Incomplete recoveryof immune function

No serious side effectsseen in 200 patients in more than 7 clinical trials Toxicityranges from mild to severe. Many problems with long-term toxicity.







PRO 140 –A Monoclonal Antibody that Binds to theHIV Entry Receptor -CCR5

Humanized monoclonal antibody

Binds to CCR5 co-receptor on white blood cells

Blocks HIV entry into white blood cells

PRO 140











PRO 140 Viral Load Reduction in >200 HIV Patients (7 clinical trials)

Subcutaneous Administration

First proof of concept for a long-acting,

self-administrable weekly HIV drug







PRO 140 Overview

FDA Fast Track designation

Currently under development in combinationwith HAART

and for an alternative to HAART

Development of PRO 140

PRO 140 evaluated in 7 clinical trials with >200 patients

Development of PRO 140 for treatment of HIV-R5 strain

Viral load drop as much as 2.5 log (>300 fold) with a single dose

Very low toxicities or side effects

No resistance observed in clinical trials

HIV R5 strain represents 90% of newly diagnosed patients and ~70% overall

Ongoing Phase 2b monotherapy extension study has exceeded 2 years of viral suppression

Phase 2b/3 Pivotal Trial –30-patient study for combination therapy w/HAART

Phase 2b/3 Investigative Trial –300-patient study for long-term monotherapy







PRO 140 for HIV: Clinical Trial OverviewTrial Stage

Study # patients Design / Findings Status P-Cl. Ph1 Ph2 Ph3

2 Phase 1 studies 54 Healthy patients, no safety concerns Complete

1302 IV Phase 1 study 39 Intravenous, single-dose VL reduction for

3 weeks Complete

2301 IV Phase 2 study 31 Intravenous, single-dose VL reduction for

3 weeks Complete

2101 SC Phase 2 study 44 Subcutaneous,long-acting, self-administered, proof-of-concept shown Complete

CD01 Phase2b 40 12-week drug-substitution monotherapy

Long-termmonotherapyextension: 14 patients with VL suppression at 12 weeks Complete Jan. 2015 Ongoing

CD02 Phase 2b/3Pivotal-Fastest path to approval 30 Combination therapy in HAART failures,

1 week efficacy + 24 weeks durability Injectionof 1stpatientOct.2015

CD03 Phase 2b/3 InvestigativeTrial –

Largest market size 300 Long-term monotherapy Injection of 1st patients Dec. 2016






Phase 2b Monotherapy Trial –PRO 140 Substitution for HAART

40 patients previously stable on daily oral combination antiretroviral therapy

Trial completed in January 2015

No drug-related serious adverse events

Evaluate the efficacy, safety and tolerability of PRO 140 monotherapy for the maintenance of viral suppression

Shifted to PRO 140 monotherapy; weekly subcutaneous injections for up to 12 weeks Trial Results: Suppressed VL

Time of


PRO 140 Monotherapy

TreatmentInterruption Study Data(1)

4 weeks



11 weeks



After11 weeks, 21 patients were qualified for extension

Patient failures due to infections unrelated to PRO 140 were excluded






Viral load measured with enhanced, single RNA copy assay

7 patientsViral load < 1 cp/mL

1 patient Viral load ~ 2 cp/mL

1 patient Viral load ~ 3 cp/mL

1 patient Viral load ~ 40 cp/mL

10 patients analyzed with assay capable of detecting a single virus

Successful Monotherapy for over 2 years






Phase 2b/3 Investigative Monotherapy Trial

Protocol cleared by FDA; first of several patients treated in Dec. 2016

300 patients well-controlled by HAART at up to 30 clinical sites



Failure criteria: viral suppression of >200 cp/mL blood two consecutive weeks




Phase 2b/3PivotalCombination Therapy Trial

First path for approval for PRO 140

To enroll 30 treatment-experienced HIV patients poorly controlled by HAART therapy. About 40 clinical sites have been cleared for enrollment Injected the 1st patient in Oct. 2015 Primary endpoint expected in 1H17: reduction in HIV viral load from baseline (0.5 log in 1 week) Secondary endpoints: Tolerability and Safety (24 weeks) Safety data to be generated from concurrent Phase 2b/3 Investigative monotherapy trial








PRO 140 Clinical and Regulatory Strategy (HIV) Phase 2b/3 Pivotal

Combination Therapy Phase 2b/3 Investigative


1st patient injected in October 2015 1stpatients injected in December 2016

Several patients concludedand are now in a rollover study due to request to receive continued access to PRO 140 48-week investigative trial

Clinical trial for first approval

underway Supported by long-term viral load reductions in ongoing Phase 2b extension study




PRO 140 for Immunologic Indications (Non-HIV)

The target of PRO 140 is CCR5, the receptor for the chemokine responsible for immune cell trafficking, T-cell migration to sites of inflammation

PRO 140 binds to CCR5 without triggering migration signals and exhibits no agonist activity when it binds (no direct stimulation) PRO 140 is a competitive inhibitor of molecules that trigger CCR5 immunologic activity

CCR5 triggering plays a crucial role in inflammatory responses: Regulation of cancer cell killing Transplantation rejection reactions


Chronic inflammation

Animal models (mice) for these diseases can be used since PRO 140 recognizes human and mouse CCR5 equivalently

The transplantation reaction, GvHD, is our first non-HIV indication for clinical investigation

(OTCQB: CYDY) 15 www.cytodyn.com




Transplantation Indication – GvHD—Phase 2b

GvHD: Graft versus Host Disease, a rejection reaction by the transplanted bone marrow (BM) stem cells producing a life-threatening reaction against the patient

Bone marrow transplant patients (AML & MDS patients) have poor survival rate due to GvHD

CCR5 has been implicated as a central feature in GvHD and positive data in an animal model is being published PRO 140 has potential to reduce the severity of GvHD and expand the patient pool for BM transplantation

FDA approved protocol: randomized, double-blind, placebo-controlled, multicenter 100-day study Enrollment of 60 BM transplant patients with AML or MDS undergoing BM stem cell transplantation Evaluate safety and efficacy of PRO 140 for prophylaxis of acute GvHD

1st patients expected to enroll in 2H17

(OTCQB: CYDY) 16 www.cytodyn.com




Experienced Management Team

Anthony Caracciolo, Executive Chairman: Former Gilead Senior Vice President of Manufacturing and Operations, member of Gilead executive committee, over 30 years of executive and senior leadership in the pharmaceutical sciences industry.

Nader Pourhassan, Ph.D., CEO: Led the development pathway for PRO 140 and was instrumental in leading the Company through several rounds of financing.

Michael Mulholland, CFO: Financial executive with 30 years of senior financial leadership with public companies in several industries. Experienced in strategic planning, corporate finance and M&A.

Denis Burger, Ph.D., Vice Chairman, CSO: Former academic Immunologist, successful biotech CEO, experienced with public company financing

Tom Boyd, Ph.D., BLA Team Leader: Formerly SVP Product Development, Progenics Pharmaceuticals Inc.; ex-Boehringer Ingelheim, Wyeth and Alteon. Experienced in project leadership and nonclinical drug development of small molecules and biologics from discovery through registration.

Nitya Ray, Ph.D., SVP-Manufacturing & CMC Team Leader: Formerly SVP Manufacturing, Progenics Pharmaceuticals Inc.; ex-Hoffmann-La Roche and Ortec International. Experienced in process development, manufacturing and quality control of biopharmaceutical, small molecule and radiopharmaceutical drugs.

(OTCQB: CYDY) 17 www.cytodyn.com






World-Class HIV Expert Advisors

Robert Schooley, MD

Paul Maddon, MD, PhD

Daniel Kuritzkes, MD

Professor of Medicine, Chief of Division of Infectious Diseases, Academic Vice Chair Department of Medicine, University of California, San Diego

An inventor of PRO 140; discovered CD4 and CCR5 interaction with HIV, Trustee of Columbia University

Professor of Medicine at Brigham & Women’s Hospital, Infectious Disease/Partners AIDS Research Center, Infectious Diseases Professor at Harvard Medical School, Principal Investigator and Chair of AIDS Clinical Trials Group (ACTG), Associate Editor for Journal of Infectious Diseases






Potential Addressable U.S. HIV Markets for PRO 140



~$0,5b Projections for 2018

Combination Therapy population size Monotherapy population size

2ndline therapy* 350,000 Patients with VL<40 cp/mL 411,380

3 classes of resistance 20,000 to 25,000

* 2ndline therapy is for patients who are onsecond HIV drug regime and primarily have one drug resistance.

Sources:(GlobalData.com –CDC.gov –AIDS.gov)

Assumes that the total HIV population in US (2018) ~ 1.365 million patients

Assumes 67% of patients with R5 strain


Assumes that 20,000 –25,000 patients have at least 3 drug classes of resistance

Total number of patients on HAART = 1.365 million x 0.57 ~ 778,100 patients

Assumes 45% as 2nd-line orhigher which yields: ~ 778,100 patients x 0.45 ~ 350,000patients


Assumes that patients with VL<40 cp/mL = 40% x 1.365 million = 614,000 patients

Patientsfor monotherapy population = 67% x 614,000 = 411,380 patients

Source: https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2000-vol-12-1.pdf






Upcoming Milestones

ODD: Orphan Drug Designation

BTD: Breakthrough Therapy DesignationEvents 1H 2017 2H 2017 2018

Phase 2b/3 Combination Therapy PIVOTAL Trial Primary Endpoint BTD ODD Submit BLA

Phase 2b/3 Monotherapy Investigative Trial 100 patients enrolled for safety arm of Combination Trial for BLA 300 patient enrollment completed Pre-BLA meeting with FDA for label expansion

Phase 2b Monotherapy extension arm 2 publications Presentation at ASM

Phase 2 GvHD 1st patient treated ODD

Non-HIV indications 3 publications




Investment Highlights

U.S. market size for HIV therapies is about $20 billion (1)

Only 56% on HAART (US only)

PRO 140 addresses HAART shortcomings: No serious side effects or toxicities No drug resistance,

Once-weekly, self-administered subcutaneous injection addresses compliance issues

Phase 2b/3 Pivotal combination therapy trial underway –Primary Endpoint results expected in 1H17 – several patients successfully completed and now in rollover study due to their request to receive continued access to PRO 140

Phase 2b/3 Investigative monotherapy trial – first several patients treated in Dec. 2016

Pipeline opportunities for Non-HIV indications: transplantation, autoimmunity, cancer and chronic inflammation Phase 2 clinical trial underway for GvHD

Source: (1) http://www.transparencymarketresearch.com/hiv-market.html

(OTCQB: CYDY) 21 www.cytodyn.com